Macrocyclic inhibitors of hepatitis C virus
    8.
    发明授权
    Macrocyclic inhibitors of hepatitis C virus 有权
    丙型肝炎病毒的大环抑制剂

    公开(公告)号:US08227407B2

    公开(公告)日:2012-07-24

    申请号:US11995835

    申请日:2008-01-16

    IPC分类号: A61K38/55 A61K38/00

    摘要: Macrocylic compounds having inhibitory activity on the replication of the hepatitis C virus (HCV) of the general formula (I) X is N, CH and where X bears a double bond it is C; R1a and R1b are hydrogen, C3-7cycloalkyl, aryl, Het, C1-6alkoxy, C1-6alkyl optionally substituted with halo, C1-6alkoxy, cyano, polyhaloC1-6alkoxy, C3-7cycloalkyl, aryl, or with Het; or R1a and R1b together with the nitrogen to which they are attached form a 4 to 6 membered heterocyclic ring which may be optionally substituted; Het being a heterocyclic ring; L is a direct bond, —O—, —O—C1-4alkanediyl-, —O—CO—, —O—C(═O)—NR5a— or —O—C(═O)—NR5a—C1-4alkanediyl-; n is 3, 4, 5, or 6; p is 1, or 2; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl, amino, mono- or diC1-6alkylamino; R4 is aryl or a saturated, a partially unsaturated or completely unsaturated 5 or 6 membered monocyclic or 9 to 12 membered bicyclic heterocyclic ring system wherein said ring system contains one nitrogen, and optionally one to three additional heteroatoms selected from O, S and N, and wherein the remaining ring members are carbon atoms; wherein said ring system may be optionally substituted; and pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I).

    摘要翻译: 对通式(I)X的丙型肝炎病毒(HCV)的复制具有抑制活性的大环化合物是N,CH,其中X具有双键,其为C; R 1a和R 1b是氢,C 3-7环烷基,芳基,Het,C 1-6烷氧基,任选被卤素,C 1-6烷氧基,氰基,多卤代C 1-6烷氧基,C 3-7环烷基,芳基或与Het取代的C 1-6烷基; 或R 1a和R 1b与它们所连接的氮一起形成可任选被取代的4至6元杂环; Het是一个杂环; L是直接键,-O - , - O-C 1-4烷二基 - , - O-CO - , - O-C(= O)-NR 5a - 或-O-C(= O)-NR 5a -C 1-4烷二基 - ; n为3,4,5或6; p为1或2; R2是氢,并且其中X是C或CH,R2也可以是C1-6烷基; R 3是氢,C 1-6烷基,C 1-6烷氧基C 1-6烷基,C 3-7环烷基,氨基,单或二C 1-6烷基氨基; R4是芳基或饱和的,部分不饱和的或完全不饱和的5或6元单环或9至12元双环杂环体系,其中所述环体系含有一个氮,以及任选地一至三个选自O,S和N的杂原子, 并且其中剩余的环成员是碳原子; 其中所述环系可以任选地被取代; 和含有化合物(I)的药物组合物和制备化合物(I)的方法。